4/22
04:05 pm
bbot
BBOT Presents Preclinical Data Demonstrating pan-KRAS Inhibitor BBO-11818 Has Robust Anti-Tumor Activity in KRAS-Mutant Preclinical Models at the AACR Annual Meeting 2026
Low
Report
BBOT Presents Preclinical Data Demonstrating pan-KRAS Inhibitor BBO-11818 Has Robust Anti-Tumor Activity in KRAS-Mutant Preclinical Models at the AACR Annual Meeting 2026
4/22
09:00 am
bbot
BBOT Announces the Appointment of Pedro J. Beltran, PhD, as Chief Executive Officer, Idan Elmelech as Chief Operating Officer, and Neil Kumar, PhD, as Executive Chairman
Medium
Report
BBOT Announces the Appointment of Pedro J. Beltran, PhD, as Chief Executive Officer, Idan Elmelech as Chief Operating Officer, and Neil Kumar, PhD, as Executive Chairman
4/21
05:30 pm
bbot
BBOT Presents Preclinical Data Showing RAS:PI3Ka Breaker BBO-10203 Inhibits PI3Ka/AKT Signaling in HER2AMP Models at the AACR Annual Meeting 2026
Medium
Report
BBOT Presents Preclinical Data Showing RAS:PI3Ka Breaker BBO-10203 Inhibits PI3Ka/AKT Signaling in HER2AMP Models at the AACR Annual Meeting 2026
4/20
04:06 pm
bbot
BBOT Granted U.S. FDA Fast Track Designation for BBO-11818 for the Treatment of Adult Patients with Advanced KRAS-Mutant Pancreatic Ductal Adenocarcinoma
Low
Report
BBOT Granted U.S. FDA Fast Track Designation for BBO-11818 for the Treatment of Adult Patients with Advanced KRAS-Mutant Pancreatic Ductal Adenocarcinoma
4/13
04:05 pm
bbot
BridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Low
Report
BridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
3/18
04:05 pm
bbot
BBOT Announces Multiple Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2026
Low
Report
BBOT Announces Multiple Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2026
3/6
10:07 am
bbot
BBOT Announces Publication in Cancer Discovery Highlighting Preclinical Data Demonstrating BBO-11818 is a Potent and Selective panKRAS Inhibitor
Low
Report
BBOT Announces Publication in Cancer Discovery Highlighting Preclinical Data Demonstrating BBO-11818 is a Potent and Selective panKRAS Inhibitor
3/6
08:03 am
bbot
BridgeBio Oncology Therapeutics (BBOT) had its price target raised by HC Wainwright from $27.00 to $29.00. They now have a "buy" rating on the stock.
Low
Report
BridgeBio Oncology Therapeutics (BBOT) had its price target raised by HC Wainwright from $27.00 to $29.00. They now have a "buy" rating on the stock.
3/5
04:05 pm
bbot
BBOT Reports Fourth Quarter and Full Year 2025 Financial Results and Update on Corporate Progress
Medium
Report
BBOT Reports Fourth Quarter and Full Year 2025 Financial Results and Update on Corporate Progress
2/12
04:05 pm
bbot
BBOT to Participate in Upcoming Investor Healthcare Conferences
Low
Report
BBOT to Participate in Upcoming Investor Healthcare Conferences
2/11
04:05 pm
bbot
BridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Medium
Report
BridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
2/10
06:05 pm
bbot
BridgeBio Oncology Therapeutics (NASDAQ:BBOT) was given a new $23.00 price target on by analysts at Stifel Nicolaus.
Medium
Report
BridgeBio Oncology Therapeutics (NASDAQ:BBOT) was given a new $23.00 price target on by analysts at Stifel Nicolaus.
1/27
02:07 pm
bbot
Biotech investor Cormorant secures $150M for another SPAC deal [Yahoo! Finance]
Low
Report
Biotech investor Cormorant secures $150M for another SPAC deal [Yahoo! Finance]